Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN (NYSE: QGEN) has announced a three-year collaboration with McGill University Centre for Microbiome Research to advance microbiome sciences. The partnership will focus on DNA extraction from low microbial biomass samples and anaerobic culturing protocols, targeting the $1.8 billion North American market. McGill will serve as a beta-testing site for new QIAGEN microbiome solutions and receive reagents for research across microbiology and genomic processing workflows. The collaboration aims to generate evidence-based knowledge for medicine and public health while supporting innovation in understanding how microbial communities impact human health and ecosystems.
QIAGEN reported strong Q3 2024 results with net sales of $502 million, representing a 5% increase at actual rates and 6% at constant exchange rates (CER), exceeding the outlook of $495 million CER. The company achieved a 29.6% adjusted operating income margin, up 3 percentage points from Q3 2023. Free cash flow increased 73% to $364 million in the first nine months of 2024. Based on solid performance, QIAGEN reaffirmed its FY 2024 net sales outlook of at least $1.985 billion CER and increased its adjusted diluted EPS outlook to at least $2.19 CER from the previous $2.10 CER.
QIAGEN has received FDA clearance for its QIAstat-Dx Meningitis/Encephalitis Panel, marking its fourth FDA clearance in 2024. The panel enables rapid diagnosis of central nervous system infections, delivering results in about one hour using real-time PCR technology, compared to traditional methods requiring 24+ hours. The test simultaneously analyzes common viral, bacterial, and fungal pathogens responsible for community-acquired meningitis/encephalitis. This approval expands QIAGEN's FDA-cleared test menu, which now covers respiratory, gastrointestinal, and central nervous system infections. The system offers unique features including cycle threshold values and amplification curves for enhanced clinical information.
QIAGEN has received FDA clearance for its QIAstat-Dx Respiratory Panel Mini test, marking its third FDA clearance in 2024. The test targets five key respiratory pathogens: influenza A, influenza B, human rhinovirus, RSV, and SARS-CoV-2. It delivers results in about one hour with minimal hands-on time using real-time PCR technology. This complements the previously cleared 21-target QIAstat-Dx Respiratory Panel Plus, offering clinicians flexibility between comprehensive and targeted testing approaches. The Mini panel is specifically designed for outpatient settings, while the Plus panel suits hospitalized patients with severe disease risk factors.
QIAGEN has announced key updates to its sample technologies solutions for non-invasive liquid biopsy applications. These enhancements are designed for use in research and clinical applications such as oncology, prenatal care, and organ transplantation. The updates include:
1. An upgraded EZ1&2 ccfDNA Kit that now supports processing of 24 samples with up to 10 mL of serum or plasma, along with a new urine protocol.
2. New QIAsymphony DSP Circulating DNA Kit (96) and QIAsymphony DSP Circulating DNA Maxi Kit (192) for fully automated extraction of ccfDNA from up to 10mL sample volume.
These updates are designed to improve results when processing larger sample volumes, important for oncology research and diagnostics. The new kits are intended for in-vitro diagnostic (IVD) use, complying with CE-IVDR and FDA regulations.
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) has announced its plans to release Q3 2024 results and hold a webcast. The press release will be issued on Wednesday, November 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. A conference call is scheduled for Thursday, November 7, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Participants have three options to join the conference call: register for a call back connection, dial-in by phone, or access the audio webcast. The company advises joining the event 5-10 minutes before the start time to avoid waiting. A conference call replay will be available after the event. For further information, interested parties can contact IR@qiagen.com.
QIAGEN is sponsoring the annual Global TB Summit from October 8-11, 2024, addressing the resurgence of tuberculosis as a leading infectious killer. The event will gather thousands of healthcare professionals, advocates, and policymakers from over 170 countries. Key points include:
- TB incident rate rose by 3.9% in 2022, with 10.6 million people falling ill and 1.3 million deaths
- QIAGEN's QuantiFERON-TB Gold Plus test plays a important role in detecting latent TB infection
- Over 35 top TB experts will discuss advancements in diagnostics and new treatment strategies
- The summit offers CPD and CME credits and emphasizes the need for renewed global efforts in TB control
- Topics include global and regional TB updates, challenges in special populations, and socioeconomic factors influencing TB
The event aims to foster collaboration and innovation in the fight against TB, with a focus on early detection and prevention strategies.
Neogen (NASDAQ: NEOG) has announced the appointment of Thierry Bernard as a new director to its Board, effective November 1, 2024. Bernard, the current CEO of QIAGEN N.V., brings extensive experience in science and technologies relevant to Neogen's markets. Jim Borel, Neogen's Board Chair, expressed confidence that Bernard's expertise will provide significant value during the company's continued growth.
Bernard has been CEO of QIAGEN since March 2020, after joining the company in 2015. His prior experience includes 15 years at bioMérieux SA, where he held various senior roles, including Corporate Vice President of Global Commercial Operations, Investor Relations, and the Greater China Region. This appointment aligns with Neogen's commitment to enhancing global food security.
QIAGEN has launched the QIAcuityDx Digital PCR System, expanding its digital PCR portfolio into clinical diagnostics. The system is 510(k) exempt in the U.S. and IVDR-certified for diagnostic use in Europe. It provides precise, absolute quantitation of target DNA and RNA, supporting liquid biopsy applications and cancer monitoring.
Key features of QIAcuityDx include:
- All-in-one instrument for IVD assays and lab-designed tests
- User-friendly software with IVD and Utility modes
- Flexible scheduling and continuous sample loading
- Processing of up to four nanoplates simultaneously
- Reduced lab space requirements and processing times
QIAGEN plans to expand the application menu, with a BCR::ABL assay for oncohematology planned for FDA submission in 2025. The company has also signed three partnerships for companion diagnostics development.
QIAGEN has received CE-marking under the new European Union IVDR framework for its QIAstat-Dx syndromic testing systems and assays. This certification includes the QIAstat-Dx Analyzer, QIAstat-Dx Rise, and panels for detecting gastrointestinal and respiratory illnesses. The achievement highlights QIAGEN's commitment to meeting high safety, quality, and performance standards, with 80% of over 180 products already transitioned to the new regulatory framework.
The QIAstat-Dx system uses multiplex real-time PCR technology to rapidly detect multiple pathogens simultaneously, delivering results in about one hour. By the end of 2023, more than 4,000 QIAstat-Dx systems had been installed globally, available in over 100 countries. The system is valued for its ease of use and reliable detection of various pathogens, contributing to better patient outcomes and antimicrobial stewardship.
FAQ
What is the current stock price of QIAGEN N.V. (QGEN)?
What is the market cap of QIAGEN N.V. (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
